Background Bullous pemphigoid (BP) is the most common autoimmune subepidermal
bullous disease of the skin. First-line treatment of systemic corticosteroids may cause …

The coexistence of psoriasis with autoimmune bullous diseases (AIBDs), particularly bullous
pemphigoid (BP), has been documented in case reports and series, as well as in …

Anti-laminin (LM) 332-type mucous membrane pemphigoid (MMP) is a rare autoimmune
bullous disease and was originally discovered as anti-epiligrin cicatricial pemphigoid. Anti …

The role of IgE autoantibodies has been demonstrated in the pathogenesis of bullous
pemphigoid for many years. Recently, omalizumab (OMZ), a humanized monoclonal anti …

Mucous membrane pemphigoid (MMP) is a heterogeneous group of rare, chronic,
subepithelial autoimmune blistering diseases (AIBDs) with predominant involvement of …

Abstract Purpose of Review Rituximab has transformed the treatment of B-cell malignancies
and rheumatoid arthritis in the past 2 decades. More recently, this anti-CD20 monoclonal …

Purpose Analyze the influence of risk factors at presentation in the long-term
immunosuppressive therapy (IMT) outcomes of ocular mucous membrane pemphigoid …

Biologic drugs are drugs made by living organisms and the term is usually limited to
monoclonal antibodies or receptors targeting specific cytokines or cells that have been …

Autoimmune bullous diseases (AIBDs) are a group of rare blistering dermatoses of the
mucous membrane and/or skin. The efficacy, safety and treatment durability of intravenous …

Ocular mucous membrane pemphigoid: novel treatment strategie... : Current Opinion in Allergy
and Clinical Immunology Ocular mucous membrane pemphigoid: novel treatment strategies …